User menu

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

Bibliographic reference Marth, Christian ; Vergote, Ignace ; Scambia, Giovanni ; Oberaigner, Willi ; Clamp, Andrew ; et. al. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.. In: European Journal of Cancer, Vol. 70, p. 111-121 (2017)
Permanent URL http://hdl.handle.net/2078.1/187407